Avidity Biosciences Inc’s filing revealed that its Chief Program Officer Gallagher Kathleen P. unloaded Company’s shares for reported $0.19 million on Jun 02 ’25. In the deal valued at $32.48 per share,5,875 shares were sold. As a result of this transaction, Gallagher Kathleen P. now holds 50,554 shares worth roughly $1.65 million.
Then, KATHLEEN GALLAGHER bought 5,875 shares, generating $182,008 in total proceeds.
Before that, Gallagher Kathleen P. sold 5,875 shares. Avidity Biosciences Inc shares valued at $190,324 were divested by the Chief Program Officer at a price of $32.40 per share. As a result of the transaction, Gallagher Kathleen P. now holds 50,554 shares, worth roughly $1.65 million.
Citigroup initiated its Avidity Biosciences Inc [RNA] rating to a Buy in a research note published on March 13, 2025; the price target was $70. A number of analysts have revised their coverage, including BMO Capital Markets’s analysts, who began to cover the stock in mid March with a ‘”an Outperform”‘ rating. Scotiabank began covering RNA with “Sector outperform” recommendation on March 07, 2025. H.C. Wainwright started covering the stock on December 20, 2024. It rated RNA as “a Buy”.
Price Performance Review of RNA
On Friday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock fall -9.88% to $32.66. Over the last five days, the stock has lost -1.54%. Avidity Biosciences Inc shares have risen nearly 12.31% since the year began. Nevertheless, the stocks have risen 16.89% over the past one year.
Levels Of Support And Resistance For RNA Stock
How much short interest is there in Avidity Biosciences Inc?
A steep rise in short interest was recorded in Avidity Biosciences Inc stocks on 2025-05-15, growing by 0.3 million shares to a total of 15.79 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 15.48 million shares. There was a rise of 1.92%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 26, 2024 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $67 price target.
